ResApp field-tests health app in the developing world

Company News

by David Chau

Digital health company, ResApp Health Ltd (ASX:RAP), is developing smartphone apps which diagnose and manage respiratory diseases – including pneumonia, asthma and bronchitis.

The company says it has shipped smartphones to a “leading global humanitarian organisation” for the purpose of field-testing its diagnostic app. ResApp has not revealed who this humanitarian organisation is just yet.

ResApp says the field evaluation is a precursor to a large-scale multi country study of the system’s ability to diagnose respiratory disease.

ResApp says this field trial will generate additional clinical evidence, and garner an in-depth understanding of the local conditions so that the company can optimise a product for essential medical personnel working in very challenging environments.

ResApp reported a net loss of $3.2 million at 30 June 2016.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.